Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
2(22%)
Results Posted
75%(3 trials)
Terminated
1(11%)

Phase Distribution

Ph phase_1
1
11%
Ph phase_2
2
22%
Ph phase_4
3
33%
Ph not_applicable
2
22%
Ph phase_3
1
11%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
3(33.3%)
N/ANon-phased studies
2(22.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(4)
Terminated(1)
Other(2)

Detailed Status

Completed4
unknown2
Terminated1
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 22 (22.2%)
Phase 31 (11.1%)
Phase 43 (33.3%)
N/A2 (22.2%)

Trials by Status

terminated111%
active_not_recruiting111%
unknown222%
completed444%
recruiting111%

Recent Activity

2 active trials
Showing 5 of 9
active_not_recruitingphase_2

Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).

NCT06253923
recruitingnot_applicable

Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma

NCT04530006
completedphase_4

Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State

NCT00693121
completednot_applicable

Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study

NCT00779324
terminatedphase_4

Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy

NCT04273737
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06253923Phase 2

Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).

Active Not Recruiting
NCT04530006Not Applicable

Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma

Recruiting
NCT00693121Phase 4

Amantadine for Treatment of Symptoms of the Post-traumatic Confusional State

Completed
NCT00779324Not Applicable

Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study

Completed
NCT04273737Phase 4

Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy

Terminated
NCT04854759Phase 3

The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms

Unknown
NCT02321761Phase 4

Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury

Unknown
NCT00970944Phase 2

Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)

Completed
NCT00416962Phase 1

Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9